Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Debt (2016 - 2019)

Fate Therapeutics' Total Debt history spans 8 years, with the latest figure at $13.9 million for Q3 2019.

  • For Q3 2019, Total Debt fell 6.28% year-over-year to $13.9 million; the TTM value through Sep 2019 reached $13.9 million, down 6.28%, while the annual FY2018 figure was $14.9 million, 0.51% up from the prior year.
  • Total Debt reached $13.9 million in Q3 2019 per FATE's latest filing, down from $14.9 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $19.7 million in Q2 2015 to a low of $6.7 million in Q2 2017.
  • Average Total Debt over 5 years is $14.7 million, with a median of $14.8 million recorded in 2018.
  • Peak YoY movement for Total Debt: soared 2540.08% in 2015, then tumbled 54.09% in 2017.
  • A 5-year view of Total Debt shows it stood at $18.2 million in 2015, then plummeted by 41.4% to $10.7 million in 2016, then soared by 38.55% to $14.8 million in 2017, then increased by 0.51% to $14.9 million in 2018, then decreased by 6.4% to $13.9 million in 2019.
  • Per Business Quant, the three most recent readings for FATE's Total Debt are $13.9 million (Q3 2019), $14.9 million (Q2 2019), and $14.9 million (Q1 2019).